Eprotirome

Eprotirome

Identifiers
IUPAC name 2-({3,5-Dibromo-4-[4-hydroxy-3-(propan-2-yl)phenoxy]phenyl}carbamoyl)acetic acid
CAS Number	355129-15-6
PubChem CID	10299876
DrugBank	DB05035
ChemSpider	8475344
UNII	958AQ7B6R1
ChEMBL	ChEMBL2035874
CompTox Dashboard (EPA)	DTXSID00189021
Chemical and physical data
Formula	C18H17Br2N2O5
Molar mass	501.151 g·mol−1
3D model (JSmol)	Interactive image
SMILES CC(C)C1=C(C=CC(=C1)OC2=C(C=C(C=C2Br)NC(=O)CC(=O)O)Br)O
InChI InChI=1S/C18H17Br2NO5/c1-9(2)12-7-11(3-4-15(12)22)26-18-13(19)5-10(6-14(18)20)21-16(23)8-17(24)25/h3-7,9,22H,8H2,1-2H3,(H,21,23)(H,24,25) Key:VPCSYAVXDAUHLT-UHFFFAOYSA-N

Eprotirome is a thyromimetic drug that has been investigated for the treatment of dyslipidemia. A Phase III trial in humans was discontinued after the drug was found to have negative effects on cartilage in dogs. ^{[1] [2]}

References

1. Saponaro, Federica; Sestito, Simona; Runfola, Massimiliano; Rapposelli, Simona; Chiellini, Grazia (2020). "Selective Thyroid Hormone Receptor-Beta (TRβ) Agonists: New Perspectives for the Treatment of Metabolic and Neurodegenerative Disorders". Frontiers in Medicine. 7: 331. doi: 10.3389/fmed.2020.00331 . ISSN   2296-858X. PMC   7363807 . PMID   32733906.
2. Unnikrishnan, A. G.; Baruah, Manash; Kalra, Sanjay (December 2012). "Thyromimetics: What does the future hold?". Indian Journal of Endocrinology and Metabolism. 16 (Suppl 2): S159 –S161. doi: 10.4103/2230-8210.104029 . ISSN   2230-8210. PMC   3603016 . PMID   23565368.